Maze Therapeutics Initiates Phase 1 Trial for MZE829, an Oral APOL1 Inhibitor, Targeting APOL1 Kidney Disease
Friday, December 15, 2023
Maze Therapeutics has announced the initiation of dosing in the Phase 1 trial of MZE829 in healthy volunteers. MZE829 is an oral small molecule designed to inhibit apolipoprotein L1 (APOL1) and address manifestations of APOL1 kidney disease.
The start of this trial is the second program identified through Maze's Compass™ platform to enter clinical development. It showcases Maze's proficiency in leveraging aggregated genetic and clinical data to develop improved medicines. Harold Bernstein, M.D., Ph.D., President of Research and Development, and Chief Medical Officer of Maze, emphasized the significance of this milestone in the company's strategy to bring potentially disease-modifying treatments to individuals with common diseases like kidney disease, using a genetically informed approach to drug discovery.
APOL1, encoded by the APOL1 gene, is associated with an elevated risk of progressive kidney diseases in the Black community. MZE829, discovered through Maze's proprietary platform, has shown promising results in preclinical studies, demonstrating tolerance and improving albuminuria in both chronic and acute humanized models of APOL1 kidney disease.
The Phase 1 trial is a randomized, placebo-controlled study assessing the safety, pharmacokinetics, food effect, and potential drug interactions of orally administered MZE829 in healthy volunteers. Data from the trial is expected to be reported in the second half of 2024, supporting the progression of MZE829 into the Phase 2 clinical program for patients.
Source: businesswire.com
